Fundraising FoxCascade Prodrug
Eugene, US · Founded 2009 · Oregon corporation · 1 known investors
Find your way into Cascade Prodrug
Sign up to see every warm intro you have to Cascade Prodrug
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cascade Prodrug team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cascade Prodrug is a preclinical-stage pharmaceutical company developing prodrug-based drug candidates, initially targeting wet age-related macular degeneration (wet AMD), with a focus on advancing through IND-enabling studies into clinical trials. The company operates in the biopharmaceutical and drug development sector.
Founders & leadership
Cascade Prodrug was founded in 2009 by August J. Sick.
AJ
August J. SickCo-Founder & Secretary
AC
Allan CochraneCo-Founder & PresidentAllan Cochrane is co-founder and president of Cascade Prodrug, a preclinical-stage biopharmaceutical company developing prodrug-based drug candidates for wet age-related macular degeneration. He brings over 40 years of experience in healthcare, diagnostics, and pharmaceutical development, including leadership roles in private and public companies, and previously served as mentor and instructor at the University of Oregon's Lundquist Center for Entrepreneurship.
LB
Lynnor B. StevensonNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$925K disclosed across 5 rounds · 2012–2020
▶$200KraisedApr 2020 · 4 investors · OtherRule 506(b)
▶$200KraisedApr 2020 · 4 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Allan CochraneExecutive Officer, Director
- August SickExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $200K
- First sale
- Mar 2020
- Incorporated
- Corporation, Oregon
- Federal exemptions
- 06b
▶$250KraisedMay 2019 · 2 investors · BiotechnologyRule 506(b)
▶$250KraisedMay 2019 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lynnor StevensonDirector
- August SickExecutive Officer, Director
- Allan G CochraneExecutive Officer, Director
- Christopher SchellingDirector
- Offering amount
- $500K
- Amount sold
- $250K
- Minimum investment
- $25K
- First sale
- Dec 2017
- Incorporated
- Corporation, Oregon
- Federal exemptions
- 06b
▶$350KraisedJun 2016 · 7 investors · BiotechnologyRule 506(b)
▶$350KraisedJun 2016 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Allan G. CochraneExecutive Officer, Director
- August SickExecutive Officer, Director
- Lynnor B. StevensonDirector
- Offering amount
- $500K
- Amount sold
- $350K
- Minimum investment
- $25K
- First sale
- Jun 2016
- Incorporated
- Corporation, Oregon
- Federal exemptions
- 06b
▶$25KraisedApr 2015 · 1 investors · BiotechnologyRule 506(b)
▶$25KraisedApr 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Allan CochraneExecutive Officer, Director
- Lynnor B. StevensonDirector
- August SickExecutive Officer, Director
- Offering amount
- $300K
- Amount sold
- $25K
- Minimum investment
- $25K
- First sale
- Mar 2015
- Incorporated
- Corporation, Oregon
- Federal exemptions
- 06b
▶$100KraisedFeb 2012 · 4 investors · BiotechnologyRule 506(b)
▶$100KraisedFeb 2012 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- August SickDirector, Promoter
- Allan CochraneExecutive Officer, Director, Promoter
- Offering amount
- $400K
- Amount sold
- $100K
- Minimum investment
- $25K
- First sale
- Jan 2012
- Incorporated
- Corporation, Oregon, 2009
- Federal exemptions
- 06, 46
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
PowerPower builds a patient-friendly platform to discover and enroll in clinical trials, serving patients seeking access to research studies and researchers seeking to improve patient recruitment. The company operates in the healthcare technology and clinical research industry.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Biogen IdecBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Companies working in the same space as Cascade Prodrug.
In the news
Frequently asked questions
- What does Cascade Prodrug do?
- Cascade Prodrug is a preclinical-stage pharmaceutical company developing prodrug-based drug candidates, initially targeting wet age-related macular degeneration (wet AMD), with a focus on advancing through IND-enabling studies into clinical trials. The company operates in the biopharmaceutical and drug development sector.
- Who founded Cascade Prodrug?
- Cascade Prodrug was founded by August J. Sick in 2009.
- Who are Cascade Prodrug's investors?
- Cascade Prodrug's investors include Elevate Capital.
- How much funding has Cascade Prodrug raised?
- Cascade Prodrug has disclosed $925K raised across 5 rounds.
- Where is Cascade Prodrug headquartered?
- Cascade Prodrug is headquartered in Eugene, US.